Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-03-11
2009-12-22
Arnold, Ernst V (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C424S451000, C424S464000, C424S489000, C424S494000, C514S456000, C514S558000
Reexamination Certificate
active
07635692
ABSTRACT:
A composition, useful in the prevention of osteoporosis, wherein said composition comprises (a) least one isoflavone and/or isoflavone glycoside, preferably genistein and/or genistin; (b) at least one polyunsaturated fatty acid; (c) optionally vitamin D, and /or one or more derivatives thereof and/or vitamin K and/or one or more derivatives thereof; and (d) optionally adjuvants and excipients in quantities as required, preferably within the range of 0.1 to 20% by weight, based on the total weight of the composition. Dietary compositions and galenical forms made therefrom and the use of said compositions for preventing osteoporosis and stimulating osteogenesis in mammals.
REFERENCES:
patent: 0 517 425 (1992-12-01), None
patent: 0 585 026 (1994-03-01), None
patent: WO 96/23504 (1996-08-01), None
patent: WO 99/66913 (1999-12-01), None
patent: WO 00/00043 (2000-01-01), None
patent: WO 00/69272 (2000-11-01), None
Treves et al. Clinical rheumatology 1992, 11(4), 558-561.
Lorenc Calcif Tissue Int 2002, 70, 395-397.
Ralston The Journal of Clinical Endocrinology & Metabolism 2002, 87(6), 2460-2466.
Derivative Merriam-Webster's Colegiate Dictionary Tenth Edition Springfield MA 1996, p. 311.
Rudnic et al. Remington's Pharmaceutical sciences 1990, 18th, 1633-1665.
Ishimi et al. (Endocrinology 1999, 140(4), 1893-1900).
Kruger et al. (Prog. Lipid Res. 1997, 36(2/3), 131-151).
Schaafsma et al. (European journal of Clinical Nutrition 2000, 54, 626-631).
Horrocks et al. (Pharmacological Research 1999, 40(3), 211 and 219).
Matsunaga et al. (Calcif Tissue Int 1999, 65, 285-289).
Patent Abstracts of Japan, vol. 2000, No. 10 of JP 2000191526 (Nov. 17, 2000).
Patent Abstracts of Japan, vol. 1999, No. 4 of JP 11009221 (Apr. 30, 1999).
Patent Abstracts of Japan, vol. 017; No. 037 of JP 04253908 (Jan. 25, 1993).
Weber, “The Role of Vitamins in the Prevention of Osteoporosis—A Brief Status Report,”Int. J. Vitamin. Nutr. Res., 69(3), pp. 194-197 (1999).
Khosla, S., Minireview: the OPG/RANKL/RANK system. Endocrinology, 2001. 142(12): p. 5050-5.
Hofbauer, L.C. and A.E. Heufelder, Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med, 2001. 79(5-6): p. 243-53.
Hofbauer, L.C., et al., Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 1999. 140(9): p. 4367-70.
Hofbauer, L.C., et al., Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone . . . ,Biochem Biophys Res Commun, 1998. 250(3): p. 776-81.
Yamagishi, T., et al., Reciprocal control of expression of mRNAs for osteoclast . . . , Evidence for the involvement of topoisomerase II in osteoclastogenesis, 2001. 142(8): p. 363.
Kruger, M.C. and D.F. Horrobin, Calcium metabolism, osteoporosis and essential fatty acids: a review. Prog Lipid Res, 1997. 36(2-3): p. 131-51.
Ellis, L., et al. Replacement of insulin receptor tyrosine residues 1162 and 1163 compromises insulin-stimulated kinase activity and uptake of . . . , Cell, 1986. 45(5): p. 721-32.
Remington:The Science and Practice of Pharmacy, vol. 1, 19th Ed. 1995, Chapter 41:Drug Absorption, Action and Disposition, section “Drug Interaction and Combination”, p. 720-23.
Das, Undurti N., Nitric Oxide as the Mediator of the Antisteoporotic Actions of Estrogen, Statins, and Essential Fatty Acids, Exper. Bio and Med. 227:88-93 (2002).
Krammer Stephanie
Riegger Christoph
Schlachter Manfred
Weber Peter
Arnold Ernst V
Bryan Cave LLP
DSM IP Assets B.V.
LandOfFree
Composition for the prevention of osteoporosis comprising a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for the prevention of osteoporosis comprising a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for the prevention of osteoporosis comprising a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4142859